Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 10/20 | 0.61 |
| ▸ | FGFR4 | P22455 | 14/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.52 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29578549 | 0.80 | FGFR1 (0.64) | FGFR1FGFR4CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL20331235 | 0.80 | FGFR1 (0.64) | FGFR1FGFR4CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL30261990 | 0.76 | FGFR1 (0.73) | FGFR1FGFR4CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15413202 | 0.76 | FGFR1 (1.00) | FGFR1FGFR4CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15434021 | 0.75 | FGFR1 (0.74) | FGFR1FGFR4CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL30262058 | 0.75 | FGFR1 (0.85) | FGFR1FGFR4CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL30046139 | 0.75 | FGFR4 (0.62) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL20330907 | 0.75 | FGFR4 (0.62) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL30261946 | 0.75 | FGFR1 (0.75) | FGFR1FGFR4CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29577570 | 0.74 | FGFR1 (0.61) | FGFR1FGFR4CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11555036-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-01-17 | — | — | US | disclosed |
| US-20220348573-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2022-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348573-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | FGFR4, FGFR2, FGFR1 | FGFR1 3/4885FGFR4 1/4885CYP3A4 42/4885 |
| US-11555036-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | FGFR4, FGFR2, FGFR1 | FGFR1 3/4885FGFR4 1/4885CYP3A4 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.